News | September 18, 2025
Novo Nordisk’s Wegovy delivered 16.6% weight loss
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
IND application for EB-003 expected in early 2026
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
